Neuralstem Inc. (NASDAQ:CUR) CEO Richard J. Daly bought 35,715 shares of the company’s stock in a transaction that occurred on Friday, November 25th. The shares were bought at an average price of $0.28 per share, for a total transaction of $10,000.20. Following the completion of the acquisition, the chief executive officer now owns 102,680 shares in the company, valued at approximately $28,750.40. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Neuralstem Inc. (NASDAQ:CUR) traded up 1.439% during midday trading on Monday, reaching $0.282. The company’s stock had a trading volume of 375,594 shares. Neuralstem Inc. has a 12 month low of $0.19 and a 12 month high of $1.20. The stock’s market capitalization is $32.36 million. The stock’s 50-day moving average is $0.28 and its 200 day moving average is $0.29.

Neuralstem (NASDAQ:CUR) last issued its earnings results on Tuesday, November 8th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.02. Neuralstem had a negative net margin of 170,366.66% and a negative return on equity of 4,420.33%. On average, analysts expect that Neuralstem Inc. will post ($0.19) earnings per share for the current fiscal year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/28/neuralstem-inc-cur-ceo-richard-j-daly-acquires-35715-shares.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sabby Management LLC purchased a new position in shares of Neuralstem during the second quarter worth approximately $1,893,000. Vanguard Group Inc. increased its position in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the period. Finally, Blair William & Co. IL purchased a new position in shares of Neuralstem during the second quarter worth approximately $122,000. Hedge funds and other institutional investors own 10.77% of the company’s stock.

Several equities research analysts recently commented on the company. Roth Capital reiterated a “buy” rating and set a $1.20 target price on shares of Neuralstem in a report on Thursday, November 10th. Brean Capital restated a “buy” rating and set a $4.00 price objective on shares of Neuralstem in a research note on Monday, September 12th. Finally, Aegis started coverage on Neuralstem in a research note on Monday, November 7th. They set a “buy” rating for the company.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

5 Day Chart for NASDAQ:CUR

Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.